|European Pharma Summit|
Kinase Inhibitors in Drug Discovery
GPCR Targeted Screening
Drug Design & Medicinal Chemistry
GTCbio and the Advisory Board would like to invite you the 3rd Kinase Inhibitors in Drug Discovery Conference. This event takes place November 16-17, 2017 in Berlin, Germany and is one of 3 co-located conferences at the European Pharma Summit.
This meeting brings together industry leaders from major pharmaceuticals, biotech companies, and top researchers from academia to provide a timely and critical summary to update significant kinase inhibitors and better understand current trends for drug design and the screening processes. Register for this event to hear recent developments in allosteric kinase inhibitors, covalent inhibitor strategies, irreversible and RAF inhibitors, mechanisms of kinase inhibitor resistance, and mutation-focused approaches towards kinase inhibition.
- Opening Plenary: Chemical Biology for Target Identification and Validation
- Technological Advances for Studying the Kinome
- Kinase Inhibitor Design
- Optimizing Target Residence Times in Kinase Drug Development
- Overcoming Therapeutic Resistance
- Closing Plenary: Hot Topics in Drug Discovery for the Future
We hope to see you there!
The 2017 Advisory Committee
|2017 Advisory Board Members|
|David Litchfield, Western University|
|Pedro Cutillas, Barts Cancer Institute|
|Stefan Knapp, University of Oxford|
|Joshua Salafsky, Biodesy Inc.|
|Doriano Fabbro, PIQUR Therapeutics|
|Gerhard Mueller, Mercachem BV|
|Ricardo Biondi, Frankfurt University Hospital|
|Michael Burnet, Synovo GmbH|
|Angus Cameron, Barts Cancer Institute|
|Hicham Alaoui, Genentech|
|Henrik Moebitz, Novartis|
|Alexei Degterev, Tufts University|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.